"Seroquel sales rose 13% to $1.3 billion in the quarter, with the bulk of sales coming from the U.S."
Funny it´s the same quarter Fanapt was released!
"Risperdal is now sold in a generic form, which means Fanapt faces a low-priced competitor at a time when the recession is forcing patients to cut back on drug spending. And the drug was never compared against AstraZeneca's(AZN) Seroquel, the leading antipsychotic drug used to treat schizophrenia."
This all above is a big reason for the sharp decline in share price after the AZN Q1 report was released!